TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma. Read more about TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma.
Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia. Read more about Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia.
Engineering Multidimensional Evolutionary Forces to Combat Cancer. Read more about Engineering Multidimensional Evolutionary Forces to Combat Cancer.
Tissue-Specific Oncogenic Activity of KRASA146T. Read more about Tissue-Specific Oncogenic Activity of KRASA146T.
Mutant and Wild-Type Isocitrate Dehydrogenase 1 Share Enhancing Mechanisms Involving Distinct Tyrosine Kinase Cascades in Cancer. Read more about Mutant and Wild-Type Isocitrate Dehydrogenase 1 Share Enhancing Mechanisms Involving Distinct Tyrosine Kinase Cascades in Cancer.
Genome-Informed Targeted Therapy for Osteosarcoma. Read more about Genome-Informed Targeted Therapy for Osteosarcoma.
Multiple Routes to Oncogenesis Are Promoted by the Human Papillomavirus-Host Protein Network. Read more about Multiple Routes to Oncogenesis Are Promoted by the Human Papillomavirus-Host Protein Network.
E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer. Read more about E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer.
Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer. Read more about Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.
